RESUMO
Abdominal pain is common in the general population and, in patients with irritable bowel syndrome, is attributed to visceral hypersensitivity. We found that oral administration of specific Lactobacillus strains induced the expression of mu-opioid and cannabinoid receptors in intestinal epithelial cells, and mediated analgesic functions in the gut-similar to the effects of morphine. These results suggest that the microbiology of the intestinal tract influences our visceral perception, and suggest new approaches for the treatment of abdominal pain and irritable bowel syndrome.
Assuntos
Dor Abdominal/fisiopatologia , Intestinos/fisiopatologia , Lactobacillus acidophilus/fisiologia , Receptores de Canabinoides/fisiologia , Receptores Opioides/fisiologia , Dor Abdominal/prevenção & controle , Administração Oral , Analgésicos Opioides/administração & dosagem , Analgésicos Opioides/farmacologia , Animais , Antagonistas de Receptores de Canabinoides , Colo/efeitos dos fármacos , Colo/microbiologia , Colo/fisiopatologia , Relação Dose-Resposta a Droga , Células HT29 , Humanos , Indóis/administração & dosagem , Indóis/farmacologia , Intestinos/efeitos dos fármacos , Intestinos/microbiologia , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Morfina/administração & dosagem , Morfina/farmacologia , Naloxona/administração & dosagem , Naloxona/farmacologia , Antagonistas de Entorpecentes/administração & dosagem , Antagonistas de Entorpecentes/farmacologia , Probióticos/administração & dosagem , Probióticos/farmacologia , Ratos , Ratos Sprague-Dawley , Receptor CB2 de Canabinoide/antagonistas & inibidores , Receptor CB2 de Canabinoide/biossíntese , Receptor CB2 de Canabinoide/fisiologia , Receptores de Canabinoides/biossíntese , Receptores Opioides/biossíntese , Receptores Opioides mu/antagonistas & inibidores , Receptores Opioides mu/biossíntese , Receptores Opioides mu/fisiologia , Reto/efeitos dos fármacos , Reto/microbiologia , Reto/fisiopatologiaRESUMO
This pilot study investigated the immunomodulatory properties of seven probiotic strains. Eighty-three healthy volunteers aged 18-62 years consumed 2 x 10(10) CFU of bacteria or a placebo (maltodextrin) over 3 weeks (D0-D21). Subjects received an oral cholera vaccine at D7 and at D14; blood and saliva samples were collected at D0, D21 and D28. Serum samples were analyzed for specific IgA, IgG and IgM, and saliva samples were analyzed for specific IgA only, by ELISA. Statistical analyses were based on Wilcoxon's signed-rank test (intragroup analyses) and exact median t-test (intergroup analyses). Salivary analysis showed no difference in specific IgA concentrations between groups. Serum analysis indicated an effect of some of the tested strains on specific humoral responses. Between D0 and D21, IgG increased in two probiotic groups, for example, Bifidobacterium lactis Bl-04 and Lactobacillus acidophilus La-14, compared with controls (P=0.01). Trends toward significant changes in immunoglobulin serum concentrations compared with controls (P<0.1) were found for six out of the seven probiotic strains. In conclusion, some strains of probiotics demonstrated a faster immune response measured with serum immunoglobulin indicators, especially IgG, although overall vaccination was not influenced. Specific strains of probiotics may thus act as adjuvants to the humoral immune response following oral vaccination.
Assuntos
Isotipos de Imunoglobulinas/biossíntese , Probióticos/farmacologia , Adolescente , Adulto , Bifidobacterium , Vacinas contra Cólera/imunologia , Vacinas contra Cólera/farmacologia , Método Duplo-Cego , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Isotipos de Imunoglobulinas/sangue , Lactobacillus , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Saliva/imunologia , Tamanho da Amostra , Estatísticas não ParamétricasRESUMO
Commercial probiotic strains for food or supplement use can be altered in different ways for a variety of purposes. Production conditions for the strain or final product may be changed to address probiotic yield, functionality, or stability. Final food products may be modified to improve flavor and other sensory properties, provide new product formats, or respond to market opportunities. Such changes can alter the expression of physiological traits owing to the live nature of probiotics. In addition, genetic approaches may be used to improve strain attributes. This review explores whether genetic or phenotypic changes, by accident or design, might affect the efficacy or safety of commercial probiotics. We highlight key issues important to determining the need to re-confirm efficacy or safety after strain improvement, process optimization, or product formulation changes. Research pinpointing the mechanisms of action for probiotic function and the development of assays to measure them are greatly needed to better understand if such changes have a substantive impact on probiotic efficacy.